Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

Junhua Mai,Zhaoqi Li,Xiaojun Xia,Jingxin Zhang,Jun Li,Haoran Liu,Jianliang Shen,Maricela Ramirez,Feng Li,Zheng Li,Kenji Yokoi,Xuewu Liu,Elizabeth A. Mittendorf,Mauro Ferrari,Haifa Shen
DOI: https://doi.org/10.1002/advs.202100166
IF: 15.1
2021-04-15
Advanced Science
Abstract:<p>Success in anticancer immune therapy relies on stimulation of tumor antigen‐specific T lymphocytes and effective infiltration of the T cells into tumor tissue. Here, a therapeutic vaccine that promotes proliferation and tumor infiltration of antigen‐specific T cells in both inflamed and noninflamed tumor types is described. The vaccine consists of STING agonist 2′3′‐cGAMP, TLR9 ligand CpG, and tumor antigen peptides that are loaded into nanoporous microparticles (<i>μ</i>GCVax). <i>μ</i>GCVax is effective in inhibiting lung metastatic melanoma, primary breast cancer, and subcutaneous colorectal cancer in their respective murine models, including functional cure of HER2‐positive breast cancer. Mechanistically, <i>μ</i>GCVax potently stimulates type I interferon expression in dendritic cells, and promotes CD8<sup>+</sup> and CD103<sup>+</sup> dendritic cell maturation and migration to lymph nodes and other lymphatic tissues. Antitumor responses are dependent on TLR9 and interferon <i>α</i>/<i>β</i> receptor signaling, and to a less extent on STING signaling. These results demonstrate a high potential for <i>μ</i>GCVax in mediating antitumor immunity in personalized cancer therapy.</p>
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
What problem does this paper attempt to address?